Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

SK bioscience Invests $2M in Sunflower Therapeutics for Research and Development Collaborations

Jul 25, 2024•almost 2 years ago

Contract Type

partnership

MedfordBiotechnology

Description

Sunflower Therapeutics announced that SK bioscience has participated in a simple agreement for future equity (SAFE) with a $2M subscription to support ongoing research and development collaborations. The partnership aims to develop an efficient manufacturing process for an accessible human papillomavirus (HPV) vaccine using an alternative protein expression host.

Company Information

Company

Sunflower Therapeutics

Location

200 Boston Ave

Medford, Massachusetts, United States

About

Sunflower Therapeutics is a unique biotech with a mission to transform bioeconomies worldwide by creating accessible solutions for protein product development and commercial manufacturing. Using our core technologies – an efficient host, data-driven methods for process development, and continuous biomanufacturing equipment – our team aims to democratize bioprocessing.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Sunflower Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months